Alnylam Pharmaceuticals, Inc. (ALNY): Price and Financial Metrics


Alnylam Pharmaceuticals, Inc. (ALNY)

Today's Latest Price: $131.84 USD

2.46 (-1.83%)

Updated Oct 23 4:00pm

Add ALNY to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

ALNY Stock Summary

  • With a one year PEG ratio of 422.91, Alnylam Pharmaceuticals Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 92.01% of US stocks.
  • With a price/sales ratio of 45.85, Alnylam Pharmaceuticals Inc has a higher such ratio than 95.55% of stocks in our set.
  • Revenue growth over the past 12 months for Alnylam Pharmaceuticals Inc comes in at 241.39%, a number that bests 97.17% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Alnylam Pharmaceuticals Inc, a group of peers worth examining would be GNTX, MXIM, FGEN, BMRN, and AMPH.
  • Visit ALNY's SEC page to see the company's official filings. To visit the company's web site, go to www.alnylam.com.

ALNY Stock Price Chart Interactive Chart >

Price chart for ALNY

ALNY Price/Volume Stats

Current price $131.84 52-week high $167.33
Prev. close $134.30 52-week low $83.06
Day low $130.72 Volume 528,900
Day high $134.75 Avg. volume 699,849
50-day MA $135.87 Dividend yield N/A
200-day MA $132.32 Market Cap 15.29B

Alnylam Pharmaceuticals, Inc. (ALNY) Company Bio


Alnylam Pharmaceuticals is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company was founded in 2002 and is based in Cambridge, Massachusetts.


ALNY Latest News Stream


Event/Time News Detail
Loading, please wait...

ALNY Latest Social Stream


Loading social stream, please wait...

View Full ALNY Social Stream

Latest ALNY News From Around the Web

Below are the latest news stories about Alnylam Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALNY as an investment opportunity.

Arcutis Announces Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma

Arcutis receives a boost with positive seborrheic dermatitis study data Arcutis Biotherapeutics Inc. (ARQT) announced positive top line data from its seborrheic dermatitis study. This Phase 2 clinical trial seeks to assess the potential of ARQ-154 in treating seborrheic dermatitis. According to the data, Roflumilast foam 0.3% dispensed once daily...

Avisol Capital Partners on Seeking Alpha | October 2, 2020

Global Antisense and RNAi Therapeutics Market Shows Strong Growth with Leading Players are Astellas Pharma Inc, Quark, Alnylam Pharmaceuticals, Inc, Dicerna Pharmaceuticals, Tekmira Pharmaceuticals, Benitec Biopharma

DBMR has added a new report titled Antisense and RNAi therapeutics market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The data and the information regarding the industry are

OpenPR | October 1, 2020

Global Antisense and RNAi Therapeutics Market Sees a Faster Rebound in the Era of COVID-19 | Industry Size, Share, Growth Factors, Development Strategy, Top Leaders-Astellas Pharma Inc, Quark, Alnylam Pharmaceuticals, Inc, Dicerna Pharmaceuticals, Tekmira

DBMR has added a new report titled Global Antisense and RNAi Therapeutics Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The data and the information regarding the industry are taken

OpenPR | September 30, 2020

Alnylam Reports Positive Topline Results from ILLUMINATE-B Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 in Children Under the Age of Six

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive topline results from the ILLUMINATE-B pediatric Phase 3 study of lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in development for the treatment of primary hyperoxaluria type 1 (PH1). ILLUMINATE-B is now the seventh Phase 3 study of an RNAi therapeutic that has yielded

Business Wire | September 30, 2020

Alnylam Highlights Prospects for Building an Industry-Leading ATTR Amyloidosis Franchise at RNAi Roundtable

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, will host an “RNAi Roundtable” webinar today at 12:00 p.m. ET, which will focus on progress across its ATTR amyloidosis programs. The Company will discuss the potential for a biannual subcutaneous dosing regimen for vutrisiran, as well as discuss ongoing Phase 3 development for patisiran and vutrisiran across the APOLLO-B, HELIOS-A, and HELIOS-B studies. The Company also annou

Business Wire | September 3, 2020

Read More 'ALNY' Stories Here

ALNY Price Returns

1-mo -1.12%
3-mo -13.89%
6-mo -7.61%
1-year 47.72%
3-year 12.30%
5-year 64.16%
YTD 14.47%
2019 57.96%
2018 -42.61%
2017 239.34%
2016 -60.23%
2015 -2.95%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8881 seconds.